(Q35024683)

English

A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

0 references

0 references

placebo-controlled trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Robert W Coombs

6

object named as

Robert W Coombs

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Scott M. Hammer

1

object named as

Scott M Hammer

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Margaret A Fischl

12

object named as

Margaret A Fischl

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

author name string

Heather Ribaudo

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Roland Bassett

3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

John W Mellors

4

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Lisa M Demeter

5

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Judith Currier

7

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Gene D Morse

8

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

John G Gerber

9

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Ana I Martinez

10

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

William Spreen

11

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Kathleen E Squires

13

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

AIDS Clinical Trials Group (ACTG) 372A Study Team

14

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

publication date

1 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

HIV Clinical Trials

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

312-324

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

The challenge of finding a cure for HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

A long-term latent reservoir for HIV-1: discovery and clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

8 July 2018

Efficacy of tenofovir as intensification of zidovudine/lamivudine/abacavir fixed-dose combination in the treatment of HIV-positive patients

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-312

21 January 2018

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-312

21 January 2018

Genotypic alteration of HAART-persistent HIV-1 reservoirs in vivo

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-312

21 January 2018

The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-312

21 January 2018

Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-312

21 January 2018

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-312

21 January 2018

Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-312

21 January 2018

A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-312

21 January 2018

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-312

21 January 2018

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-312

21 January 2018

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

25 October 2018

Intensification of background antiretroviral therapy with abacavir during low-level failure may restore optimal suppression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

25 October 2018

Vasectomy and human immunodeficiency virus type 1 in semen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3108099

25 October 2018

Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21239359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1310/HCT1105-312

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35024683&oldid=1946345418"